Pfizer sees ‘at least’ $4B by 2024-end from cost realignment program
The Fly

Pfizer sees ‘at least’ $4B by 2024-end from cost realignment program

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App